Project Grant HT94252410093
Award Date
9/15/24
Completion Date
9/14/27
Dollars Obligated
$1.4M
Federal Agency
Defense Health Agency
Federal Grant Program
12.420
Assistance Type
Project Grant
Place of Performance
Houston, TX 77030, USA
Similar Awards
This $1,619,723 federal Project Grant award from the Department of Defense's Defense Health Agency under the Military Medical Research and Development program (CFDA 12.420) provides funding to The University of Texas MD Anderson Cancer Center to conduct research targeting novel mediators of breast cancer brain metastasis. The award period runs from April 1, 2024 to March 31, 2027, with the goal of developing new treatments, improving patient care, and advancing scientific understanding in this...
The University of Texas MD Anderson Cancer Center was awarded a $1,214,999 Project Grant from the Department of the Army Medical Command under the Military Medical Research and Development program (CFDA 12.420). The grant will fund research to identify collateral lethal targets in prostate cancer from September 1, 2021 through August 31, 2024. The Military Medical Research and Development program supports biomedical research that transforms military and public health care through innovative...
The U.S. Defense Health Agency has awarded a $7,001,734 Project Grant to The University of Texas MD Anderson Cancer Center to advance the understanding of metastatic breast cancer through the development of a comprehensive research platform. The grant, which runs from August 15, 2024 to August 14, 2028, is funded under the Military Medical Research and Development (CFDA 12.420) program. The project aims to drive innovative cancer research and explore new approaches to prevention, diagnosis,...
This $3,945,543 Project Grant award from the Defense Health Agency under the Military Medical Research and Development program (CFDA 12.420) supports cancer research and care initiatives at the University of Texas MD Anderson Cancer Center (MD Anderson). The award will fund a 4-year clinical research extension project to advance progress, precision, and equity in breast cancer care. MD Anderson, a leading comprehensive cancer center, will utilize the funding to conduct research activities that...
The University of Texas MD Anderson Cancer Center received a $567,000 Project Grant from the Defense Health Agency under the Military Medical Research and Development program (CFDA 12.420). The grant, awarded on September 1, 2024, will fund research targeting myeloid mimicry in renal medullary carcinoma, with a completion date of August 31, 2027. Through this federal grant, MD Anderson Cancer Center will conduct innovative scientific studies, ranging from basic laboratory research to advanced...
The University of Texas MD Anderson Cancer Center will receive $2,172,614 under a three-year Project Grant from the Department of the Army Medical Command's Military Medical Research and Development program (CFDA 12.420). The grant will fund research from September 2022 to September 2025 to develop an integrated genomic and therapeutic strategy for androgen-indifferent prostate cancers. The Military Medical Research and Development program supports biomedical research with the goals of improving...
The University of Texas MD Anderson Cancer Center will receive $1,066,238 under a three-year Project Grant from the Department of the Army Medical Command's Military Medical Research and Development program (CFDA 12.420). The grant will support research from September 2022 to September 2025 to develop an integrated genomic and therapeutic strategy for androgen-indifferent prostate cancers. Through basic, applied, and advanced biomedical research, the Military Medical Research and Development...
This federal Project Grant award from the Defense Health Agency, part of the Military Medical Research and Development program (CFDA 12.420), provides $1,408,488 to the University of Texas MD Anderson Cancer Center to conduct research on social isolation, loneliness, and health outcomes among prostate cancer survivors. The project aims to investigate these factors and their impact on health, with the goal of improving survivorship care for prostate cancer patients. The award was made on...
The Department of the Army Medical Command awarded a $249,999 Project Grant to The University of Texas M.D. Anderson Cancer Center through the Military Medical Research and Development program. This three-year grant will fund research from September 2022 to August 2025 to revisit antiangiogenic therapy and target prostate cancer metabolism. The Military Medical Research and Development program, designated by CFDA #12.420, supports basic, applied, and advanced biomedical research with the goals...
The University of Texas MD Anderson Cancer Center received a $647,990 Project Grant award from the Defense Health Agency under the Military Medical Research and Development program (CFDA 12.420). This three-year grant, effective June 1, 2024, supports research to investigate cell plasticity and epigenetic reprogramming mechanisms underlying the transition of well-differentiated to de-differentiated liposarcoma. The funding will enable basic research, translational studies, and potentially future...